ArticleBMC infectious diseases2026
Immunological consequences of delayed exposure to hepatitis A virus: evidence consistent with CD8
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis A virus (HAV) infection has traditionally occurred during early childhood in high-endemic settings but is increasingly affecting adolescents and adults in regions undergoing epidemiological transition, where improvements in sanitation delay primary exposure. Adult HAV infection is associated with more severe clinical disease, and prior work has implicated CD8 + cytotoxic T lymphocyte responses and cytokine-driven bystander immune activation in hepatocyte injury; however, the immunological correlates underlying age-dependent severity in populations undergoing active epidemiological transition remain incompletely characterised.
methodsWe analysed statewide surveillance data from Kerala, India (2020-2024), comprising 34,118 confirmed or probable HAV cases, to characterise temporal, seasonal, and geographic trends. Within this framework, we conducted an immunological substudy of 180 patients with confirmed acute HAV infection, stratified by age at infection used as an operational proxy for early (< 18 years) versus delayed (≥ 18 years) primary exposure in a population where improvements in sanitation have progressively shifted first infection to later ages. Clinical severity, hospitalisation, liver biochemistry, peripheral CD8 + T-cell responses (IFN-γ ELISPOT), plasma cytokines, and viral load were assessed. Multivariable logistic regression and sensitivity analyses were used to identify factors associated with moderate-to-severe disease.
resultsSurveillance data demonstrated a marked increase in reported HAV cases after 2021, with pronounced post-monsoon seasonality and geographic clustering. In the immunological cohort, individuals infected at ≥ 18 years had significantly higher odds of moderate-to-severe disease compared with those infected earlier (adjusted odds ratio 8.42, 95% CI 3.21-22.08). Moderate-to-severe disease occurred in 69.5% of participants with delayed exposure compared with 7.7% of those with early exposure. Delayed exposure was associated with stronger peripheral CD8 + T-cell IFN-γ responses and higher plasma IFN-γ and TNF-α concentrations, alongside higher aminotransferase levels and increased hospitalisation rates. Viral load did not differ significantly between age groups. Findings were robust across multiple sensitivity analyses.
conclusionsIn this transitioning setting, adult primary HAV infection is associated with increased clinical severity and heightened peripheral cellular immune responses, independent of viral load. These peripheral immune findings are consistent with an immune-mediated contribution to liver injury during adult HAV infection. The findings support consideration of public health strategies aimed at preventing delayed exposure, including prioritisation of childhood hepatitis A vaccination in regions experiencing similar epidemiological transitions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.